North America Point-of-Care Molecular Testing for Infectious Diseases Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. North America Point-of-Care Molecular Testing for Infectious Diseases Market Regional Analysis

6.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue 2021-2031 (US$ Billion)

6.3 North America Point-of-Care Molecular Testing for Infectious Diseases Market Forecast Analysis

7. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Diseases

7.1 HIV Testing

7.1.1 Overview
7.1.2 HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

7.2 Influenza Testing

7.2.1 Overview
7.2.2 Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

7.3 Sexually Transmitted Diseases Testing

7.3.1 Overview
7.3.2 Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

7.4 Hepatitis C Virus Testing

7.4.1 Overview
7.4.2 Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

7.5 Tropical Diseases Testing

7.5.1 Overview
7.5.2 Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

7.6 Respiratory Infection Testing

7.6.1 Overview
7.6.2 Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

7.7 Hospital Acquired Infections

7.7.1 Overview
7.7.2 Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

7.8 Strep

7.8.1 Overview
7.8.2 Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Technology

8.1 Lateral Flow Assay

8.1.1 Overview
8.1.2 Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

8.2 Dipsticks

8.2.1 Overview
8.2.2 Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

8.3 Microfluidics

8.3.1 Overview
8.3.2 Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

8.4 Molecular Diagnostics

8.4.1 Overview
8.4.2 Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

8.5 Immunoassays

8.5.1 Overview
8.5.2 Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

8.6 Solid Phase

8.6.1 Overview
8.6.2 Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

9. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Prescription Testing

9.1 Prescription Based Testing

9.1.1 Overview
9.1.2 Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

9.2 OTC Testing

9.2.1 Overview
9.2.2 OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

10. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Sample

10.1 Blood Sample

10.1.1 Overview
10.1.2 Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

10.2 Urine Sample

10.2.1 Overview
10.2.2 Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

10.3 Nasal and Oropharyngeal Swabs Sample

10.3.1 Overview
10.3.2 Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast, 2021-2031 (US$ Billion)

11. North America Point-of-Care Molecular Testing for Infectious Diseases Market – North America Analysis

11.1 Overview

11.2 North America

11.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Key Country, 2024 and 2031 (%)
11.2.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast Analysis – by Country
11.2.1.1 US: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)

11.2.1.1.1 US: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Diseases
11.2.1.1.2 US: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Technology
11.2.1.1.3 US: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Prescription Testing
11.2.1.1.4 US: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Sample

11.2.1.2 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)

11.2.1.2.1 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Diseases
11.2.1.2.2 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Technology
11.2.1.2.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Prescription Testing
11.2.1.2.4 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Sample

11.2.1.3 Mexico : North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)

11.2.1.3.1 Mexico : North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Diseases
11.2.1.3.2 Mexico : North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Technology
11.2.1.3.3 Mexico : North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Prescription Testing
11.2.1.3.4 Mexico : North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Sample

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 Abbott Laboratories

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 Agilent Technologies Inc

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Becton Dickinson and Co

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 Bio-Rad Laboratories Inc

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 Cardinal Health Inc,

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

14.6 Danaher Corp

14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments

14.7 Cue Health Inc,

14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments

14.8 QuidelOrtho Corp

14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments

14.9 Thermo Fisher Scientific Inc

14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments

14.10 F. Hoffmann-La Roche Ltd.

14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

North America Point-of-Care Molecular Testing for Infectious Diseases Market